Accolade, Inc. (ACCD)
$
7.02
Key metrics
Financial statements
Free cash flow per share
-0.1228
Market cap
575.6 Million
Price to sales ratio
1.2885
Debt to equity
0.0910
Current ratio
2.6303
Income quality
0.0375
Average inventory
0
ROE
-0.4461
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Accolade, Inc., together with its subsidiaries, develops and offers technology-enabled solutions designed to assist individuals in navigating the complexities of the healthcare system and their workplace benefits across the United States. The company showcases a robust revenue of $414,292,000.00 which illustrates its consistent growth trajectory. With a gross profit ratio of 0.46 Accolade signifies efficiency in its production and sales operations. Operating expenses total $306,513,000.00 encompassing various operational costs incurred during its initiatives. Additionally, the net total of other income and expenses is $15,883,000.00 which reflects the company’s non-core financial activities. Accolade has also showcased its financial prowess by earning an interest income of $0.00 through strategic investments. The organization provides an integrated platform that leverages cloud-based technology and multimodal support from a dedicated team comprising health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists, ensuring employers offer their employees and their families a reliable resource for their health and benefits needs. Established in 2007 and headquartered in Plymouth Meeting, Pennsylvania, Accolade represents a formidable presence in the healthcare tech sector. In the investment realm, the stock is affordable at $7.02 making it appealing for budget-conscious investors. The average trading volume of the stock is 1,565,611.00 indicating robust liquidity and interest among investors. With a market capitalization of $575,591,590.00 Accolade, Inc. is categorized as a small-cap player, indicating significant growth potential. It plays a pivotal role in the Medical - Healthcare Information Services industry, where it contributes significantly to shaping the overall market landscape. Moreover, as part of the Healthcare sector, Accolade is dedicated to driving innovation and growth, striving to enhance the relationship between individuals and their healthcare experiences.
What is Accolade, Inc. (ACCD)'s stock forecast?
Analysts predict Accolade, Inc. stock to fluctuate between $3.08 (low) and $9.67 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Accolade, Inc.'s market capitalization?
As of 2025-04-07, Accolade, Inc.'s market cap is $575,591,590, based on 81,993,104 outstanding shares.
How does Accolade, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Accolade, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Accolade, Inc. (ACCD) stock?
To buy Accolade, Inc. (ACCD) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ACCD. Place an order (Market, Limit, etc.).
What is the best time to invest in Accolade, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Accolade, Inc. perform in the last earnings report?
Revenue: $414,292,000 | EPS: -$1.33 | Growth: -79.38%.
Where can I find Accolade, Inc.'s investor relations reports?
Visit https://www.accolade.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Accolade, Inc.?
You can explore historical data from here
What is the all-time high and low for Accolade, Inc. stock?
All-time high: $56.72 (2021-02-10) | All-time low: $3.08 (2024-11-04).
What are the key trends affecting Accolade, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
NEW YORK & TORONTO--(BUSINESS WIRE)-- #Advertising--Klick Health is capping off The One Club's Creative Week tonight with a groundbreaking win, becoming the first health agency in The One Show's 52-year history to ever be named an Agency of the Year. As The One Show's 2025 Independent Agency of the Year and the recipient of 83 campaign accolades over the course of the week, Klick is helping signal a major advertising industry shift as health creativity increasingly takes center stage. “Klick Health's recognit.
reuters.com
Pernod Ricard has completed the sale of its international wine portfolio, including brands like Jacob's Creek, to Accolade Wines owner Australian Wine Holdco, it said on Wednesday.
businesswire.com
SAN FRANCISCO & SEATTLE--(BUSINESS WIRE)-- #HealthWayFinding--Today Transcarent announced the successful completion of its merger with Accolade, the leading health advocacy, expert medical opinion, and virtual primary care company in the market. The combined organization now serves over 20 million Members and more than 1,700 employer and health plan clients as the One Place for Health and Care. With the completion of the transaction, Transcarent will offer a health and care experience that is unmatched in its abil.
zacks.com
Here is how Accolade (ACCD) and Casella (CWST) have performed compared to their sector so far this year.
businesswire.com
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Accolade, Inc. (NASDAQ: ACCD) to Transcarent for $7.03 per share in cash is fair to Accolade shareholders. Halper Sadeh encourages Accolade shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Accolade and its board.
prnewswire.com
Effort broadens healthcare access and removes barriers to primary care and weight management services SEATTLE , Feb. 4, 2025 /PRNewswire/ -- Today, Accolade, Inc. (NASDAQ: ACCD) announced that its direct-to-consumer virtual healthcare offering, PlushCare, is now accepting Medicare Part B, expanding care access to 64 million beneficiaries across all 50 states. PlushCare offers quality primary care, clinical weight management services, and mental health support from leading providers.
prnewswire.com
NEW YORK , Jan. 10, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Accolade (NASDAQ: ACCD) and its board of directors concerning the proposed acquisition of the company by Transcarent. Stockholders will receive $7.03 for each share of Accolade stock that they hold.
zacks.com
Accolade (ACCD) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.28 per share a year ago.
businesswire.com
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Accolade, Inc. (NasdaqGS: ACCD) to Transcarent. Under the terms of the proposed transaction, shareholders of Accolade will receive $7.03 in cash for each share of Accolade that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the considera.
benzinga.com
Transcarent agreed to buy Accolade Inc ACCD Wednesday for $621 million.
See all news
